DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

July 19, 2016 updated by: Alnylam Pharmaceuticals
The purpose of this study is to characterize the frequency of TTR mutations in subjects suspected of having cardiac amyloidosis

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
1010

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Anderlecht, Belgium
        • Clinical Trial Site
      • Brussels, Belgium, 1020
        • Clinical Trial Site
      • Hasselt, Belgium
        • Clinical Trial Site
      • Roeselare, Belgium
        • Clinical Trial Site
  • Brazil
      • Blumenau, Brazil
        • Clinical Trial Site
  • France
      • Bordeaux, France
        • Clinical Trial Site
      • Toulouse Cedex, France
        • Clinical Trial Site
      • Vandoeuvre-lès-Nancy, France
        • Clinical Trial Site
  • Spain
      • Barcelona, Spain, 8003
        • Clinical Trial Site
      • Barcelona, Spain, 8907
        • Clinical Trial Site
      • Madrid, Spain
        • Clinical Trial Site
      • Seville, Spain
        • Clinical Trial Site
  • United Kingdom
      • Cardiff, United Kingdom
        • Clinical Trial Site
      • London, United Kingdom, SW17 0QT
        • Clinical Trial Site
      • London, United Kingdom, NW1 2BU
        • Clinical Trial Site
  • United States
    • Arkansas
      • Little Rock, Arkansas, United States
        • Clinical Trial Site
    • California
      • Bakersfield, California, United States
        • Clinical Trial Site
      • La Mesa, California, United States
        • Clinical Trial Site
      • Los Angeles, California, United States, 90095
        • Clinical Trial Site
      • Los Angeles, California, United States, 90073
        • Clinical Trial Site
      • San Francisco, California, United States
        • Clinical Trial Site
      • Torrance, California, United States
        • Clinical Trial Site
    • Colorado
      • Aurora, Colorado, United States
        • Clinical Trial Site
    • District of Columbia
      • Washington, District of Columbia, United States, 20422
        • Clinical Trial Site
      • Washington, District of Columbia, United States, 20010
        • Clinical Trial Site
      • Washington, District of Columbia, United States, 20052
        • Clinical Trial Site
    • Florida
      • Tampa, Florida, United States
        • Clinical Trial Site
    • Georgia
      • Athens, Georgia, United States
        • Clinical Trial Site
      • Atlanta, Georgia, United States, 30303
        • Clinical Trial Site
      • Atlanta, Georgia, United States, 30310
        • Clinical Trial Site
      • Macon, Georgia, United States
        • Clinical Trial Site
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Clinical Trial Site
      • Chicago, Illinois, United States, 60637
        • Clinical Trial Site
      • Chicago, Illinois, United States, 60612
        • Clinical Trial Site
    • Indiana
      • Merrillville, Indiana, United States
        • Clinical Trial Site
    • Maryland
      • Baltimore, Maryland, United States
        • Clinical Trial Site
    • Massachusetts
      • Boston, Massachusetts, United States
        • Clinical Trial Site
      • Springfield, Massachusetts, United States
        • Clinical Trial Site
    • Michigan
      • Detroit, Michigan, United States
        • Clinical Trial Site
    • Mississippi
      • Jackson, Mississippi, United States
        • Clinical Trial Site
    • Missouri
      • St. Louis, Missouri, United States
        • Clinical Trial Site
    • New Jersey
      • Camden, New Jersey, United States
        • Clinical Trial Site
    • New York
      • Bronx, New York, United States
        • Clinical Trial Site
      • Rochester, New York, United States
        • Clinical Trial Site
      • Rosedale, New York, United States
        • Clinical Trial Site
      • Williamsville, New York, United States
        • Clinical Trial Site
    • North Carolina
      • Durham, North Carolina, United States
        • Clinical Trial Site
    • Ohio
      • Cleveland, Ohio, United States
        • Clinical Trial Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • Clinical Trial Site
      • Philadelphia, Pennsylvania, United States, 19102
        • Clinical Trial Site
      • Pittsburgh, Pennsylvania, United States
        • Clinical Trial Site
    • South Carolina
      • Charleston, South Carolina, United States
        • Clinical Trial Site
    • Texas
      • Fort Worth, Texas, United States
        • Clinical Trial Site
      • Plano, Texas, United States
        • Clinical Trial Site
    • Virginia
      • Falls Church, Virginia, United States
        • Clinical Trial Site
      • Norfolk, Virginia, United States
        • Clinical Trial Site
      • Richmond, Virginia, United States, 23298
        • Clinical Trial Site
      • Richmond, Virginia, United States, 23249
        • Clinical Trial Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Subjects Suspected of Having Familial Amyloidotic Cardiomyopathy (FAC)

Description

Inclusion Criteria:

  • Males or females >18 years old
  • History of evidence suggestive of cardiac amyloidosis
  • Subject is willing and able to comply with protocol required assessments and provide written informed consent

Exclusion Criteria:

  • Known diagnosis of primary (AL) amyloidosis
  • Known diagnosis of hereditary cardiomyopathy or cardiomyopathy due to aortic stenosis
  • Patient is currently pregnant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Familial Amyloidotic Cardiomyopathy (FAC)

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Proportion of patients with of Transthyretin (TTR) mutations
Time Frame: Baseline
Blood will be sequenced for the presence of TTR gene mutations
Baseline

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Assessment of the presence of amyloid in tissue
Time Frame: Day 30
An optional fine-needle aspirate of the abdominal fat pad will be collected
Day 30
Quantification of biomarkers of cardiac function in serum
Time Frame: Day 30
Biomarkers that assess cardiac function will be quantified from serum
Day 30
Measurement of echocardiogram parameters
Time Frame: Day 30
Cardiac structure and function will be measured by echocardiogram
Day 30
New York Heart Association (NYHA) Functional Classification
Time Frame: Day 30
NYHA Functional Classification will be determined
Day 30
Results from 6-Minute Walk Test
Time Frame: Day 30
Total distance walked in 6 minutes will be measured
Day 30

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Alnylam Pharmaceuticals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 1, 2014

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 1, 2016

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 1, 2016

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 22, 2014

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 26, 2014

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 30, 2014

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 20, 2016

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 19, 2016

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • ALN-TTR-NT-002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings